E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 6/13/2006 in the Prospect News Biotech Daily, Prospect News Convertibles Daily and Prospect News High Yield Daily.

Allos Therapeutics files $100 million shelf

By Jennifer Chiou

New York, June 13 - Allos Therapeutics, Inc. registered to sell up to $100 million of securities in an S-3 filing with the Securities and Exchange Commission.

Covered by the shelf are common stock, preferred stock, depositary shares, debt securities, warrants and units. Debt securities and preferred stock may be structured as convertibles.

Proceeds will go toward clinical trials and other research and development activities to commercialize Efaproxyn, a synthetic small molecule designed to sensitize hypoxic or oxygen-deprived areas of tumors during radiation therapy.

Westminster, Colo.-based Allos Therapeutics is a biopharmaceutical company focused on small molecule therapeutics for cancer.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.